[go: up one dir, main page]

CY1119419T1 - C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε) - Google Patents

C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε)

Info

Publication number
CY1119419T1
CY1119419T1 CY20171100961T CY171100961T CY1119419T1 CY 1119419 T1 CY1119419 T1 CY 1119419T1 CY 20171100961 T CY20171100961 T CY 20171100961T CY 171100961 T CY171100961 T CY 171100961T CY 1119419 T1 CY1119419 T1 CY 1119419T1
Authority
CY
Cyprus
Prior art keywords
heronal
uae
vase
training
prevention
Prior art date
Application number
CY20171100961T
Other languages
English (en)
Inventor
Cynthia GALLAGHER
Stephen Ruddy
Mark Cornell MANNING
Original Assignee
Shire Viropharma Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119419(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Incorporated filed Critical Shire Viropharma Incorporated
Publication of CY1119419T1 publication Critical patent/CY1119419T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Αποκαλύπτονται συνθέσεις και μέθοδοι για την αγωγή και/ή πρόληψη διαταραχών συνδεόμενων με ανεπάρκεια αναστολέα C1 εστεράσης.
CY20171100961T 2013-03-15 2017-09-12 C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε) CY1119419T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Publications (1)

Publication Number Publication Date
CY1119419T1 true CY1119419T1 (el) 2018-03-07

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100961T CY1119419T1 (el) 2013-03-15 2017-09-12 C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε)
CY20191100308T CY1121653T1 (el) 2013-03-15 2019-03-15 C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100308T CY1121653T1 (el) 2013-03-15 2019-03-15 C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης

Country Status (31)

Country Link
US (9) US9616111B2 (el)
EP (3) EP2968434B1 (el)
JP (9) JP6184581B2 (el)
KR (4) KR20150135242A (el)
CN (2) CN111529708A (el)
AU (3) AU2014232912A1 (el)
BR (1) BR112015023207A8 (el)
CA (2) CA3054718A1 (el)
CY (2) CY1119419T1 (el)
DE (1) DE202014011208U1 (el)
DK (2) DK3290046T3 (el)
EA (1) EA201591278A1 (el)
ES (2) ES2639833T3 (el)
GB (1) GB2530921B (el)
HK (2) HK1220403A1 (el)
HR (2) HRP20171269T1 (el)
HU (2) HUE036224T2 (el)
IL (2) IL241549B (el)
LT (2) LT3290046T (el)
ME (2) ME02865B (el)
MX (3) MX373965B (el)
NZ (2) NZ751555A (el)
PL (2) PL3290046T3 (el)
PT (2) PT3290046T (el)
RS (2) RS56285B1 (el)
SG (2) SG10201707598QA (el)
SI (2) SI2968434T1 (el)
SM (2) SMT201700415T1 (el)
TR (1) TR201900319T4 (el)
WO (1) WO2014145519A2 (el)
ZA (3) ZA201507604B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036224T2 (hu) 2013-03-15 2018-06-28 Shire Viropharma Inc C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra
EP3071219B1 (en) * 2013-11-22 2018-11-14 Shire Viropharma Incorporated Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
CN107257683A (zh) * 2015-02-20 2017-10-17 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
CN108025047B (zh) * 2015-05-28 2021-11-19 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
EP3377093B1 (en) 2015-11-19 2022-07-13 Takeda Pharmaceutical Company Limited Recombinant human c1 esterase inhibitor and uses thereof
AU2017305856B2 (en) 2016-08-05 2024-09-12 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
EP3504648A1 (en) * 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
MX2019013711A (es) * 2017-05-16 2020-01-30 Octapharma Ag Preparacion de inhibidor de c1 esterasa.
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
MX2020008969A (es) 2018-02-28 2021-02-16 Pharming Intellectual Property B V Tratamiento y prevencion de preeclampsia.
EP3845652A4 (en) 2018-06-22 2022-04-13 JUNTEN BIO Co., Ltd. ANTIBODIES FOR INDUCING IMMUNTOLERANCE, INDUCED LYMPHOCYTE AND THERAPEUTIC METHOD WITH CELL THERAPY AGENT USING INDUCED LYMPHOCYTE
US20210260124A1 (en) 2018-06-22 2021-08-26 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
JPWO2019245039A1 (ja) 2018-06-22 2021-06-24 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 感染性免疫寛容を惹起するための組成物
JPWO2021124793A1 (el) * 2019-12-16 2021-06-24
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
WO2023280981A1 (en) 2021-07-09 2023-01-12 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DK0716611T3 (da) * 1993-09-01 2002-05-21 Sanquin Bloedvoorziening Fremgangsmåde til at reducere myocardielæsion under akut myocardieinfarkt
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
ATE382635T1 (de) 2000-01-31 2008-01-15 Pharming Intellectual Pty Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
HUE052154T2 (hu) 2003-05-16 2021-04-28 Pharming Intellectual Property B V Rövid felezési idejû C1 inhibitor tranziens kezeléshez
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
SI1940457T1 (sl) 2005-10-21 2013-04-30 Catalyst Biosciences, Inc. Modificirane proteaze, ki inhibirajo komplementno aktivacijo
PT1965831E (pt) * 2005-12-21 2011-10-19 Pharming Intellectual Pty Bv Uso de inibidor c1 para a prevenção da lesão isquémia-reperfusão
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
DK2526962T3 (da) 2007-02-12 2019-10-07 Csl Behring Gmbh Therapeutic application of Kazal-type serine protease inhibitors
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
PT2488203T (pt) 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
KR102022231B1 (ko) 2011-12-22 2019-09-19 체에스엘 베링 게엠베하 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도
JP2015512370A (ja) 2012-03-16 2015-04-27 ベルローズ ファーマ，インコーポレーテッド Ｃ１−阻害剤のポリマーコンジュゲート
WO2014160499A2 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
HUE036224T2 (hu) 2013-03-15 2018-06-28 Shire Viropharma Inc C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra

Also Published As

Publication number Publication date
SMT201700415T1 (it) 2017-11-15
HRP20171269T1 (hr) 2017-11-03
HK1220403A1 (zh) 2017-05-05
MX2021011946A (es) 2021-11-17
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
JP6473535B2 (ja) 2019-02-20
CY1121653T1 (el) 2020-07-31
ES2713004T3 (es) 2019-05-17
ZA201806793B (en) 2020-01-29
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
ME03326B (me) 2019-10-20
JP2018119001A (ja) 2018-08-02
TR201900319T4 (tr) 2019-02-21
HRP20190270T1 (hr) 2019-04-05
CN111529708A (zh) 2020-08-14
PT2968434T (pt) 2017-09-18
US20160015795A1 (en) 2016-01-21
JP2018119000A (ja) 2018-08-02
JP6473534B2 (ja) 2019-02-20
JP2019073544A (ja) 2019-05-16
BR112015023207A8 (pt) 2018-01-23
CA3054718A1 (en) 2014-09-18
US9616111B2 (en) 2017-04-11
US20200261556A1 (en) 2020-08-20
DK3290046T3 (en) 2019-03-18
GB2530921B (en) 2017-09-20
BR112015023207A2 (pt) 2017-11-21
NZ751555A (en) 2021-07-30
KR102579789B1 (ko) 2023-09-15
ZA201507604B (en) 2018-05-30
EP2968434A4 (en) 2016-03-02
AU2018229558A1 (en) 2018-10-04
KR102430453B1 (ko) 2022-08-05
KR20210021146A (ko) 2021-02-24
US11534482B2 (en) 2022-12-27
AU2018229558B2 (en) 2020-03-05
JP6184581B2 (ja) 2017-08-23
PL3290046T3 (pl) 2019-05-31
JP6877470B2 (ja) 2021-05-26
JP6877472B2 (ja) 2021-05-26
JP2016516073A (ja) 2016-06-02
SI2968434T1 (sl) 2017-11-30
LT2968434T (lt) 2017-09-25
KR20150135242A (ko) 2015-12-02
JP2021088599A (ja) 2021-06-10
JP2017105847A (ja) 2017-06-15
CA2904543C (en) 2019-10-08
SG11201507616VA (en) 2015-10-29
EP2968434B1 (en) 2017-06-28
AU2020203183A1 (en) 2020-06-04
GB2530921A (en) 2016-04-06
AU2020203183B2 (en) 2022-06-02
CN105517559A (zh) 2016-04-20
KR20220070049A (ko) 2022-05-27
PT3290046T (pt) 2019-02-18
LT3290046T (lt) 2019-03-12
JP6473536B2 (ja) 2019-02-20
US20180153972A1 (en) 2018-06-07
JP2019073545A (ja) 2019-05-16
US20180085441A1 (en) 2018-03-29
SMT201900141T1 (it) 2019-05-10
IL241549B (en) 2020-08-31
ME02865B (me) 2018-04-20
SG10201707598QA (en) 2017-10-30
HUE036224T2 (hu) 2018-06-28
US10105423B2 (en) 2018-10-23
IL276153A (en) 2020-09-30
WO2014145519A3 (en) 2014-12-31
JP6877471B2 (ja) 2021-05-26
US10080788B2 (en) 2018-09-25
DK2968434T3 (en) 2017-09-11
MX373965B (es) 2025-03-05
DE202014011208U1 (de) 2018-08-23
US20190160157A1 (en) 2019-05-30
EA201591278A1 (ru) 2016-03-31
JP6422520B2 (ja) 2018-11-14
SI3290046T1 (sl) 2019-04-30
WO2014145519A2 (en) 2014-09-18
US20180110844A1 (en) 2018-04-26
ES2639833T3 (es) 2017-10-30
MX2015011281A (es) 2016-03-03
AU2014232912A1 (en) 2015-09-03
HK1250912B (zh) 2020-01-10
JP2019073546A (ja) 2019-05-16
KR20210129267A (ko) 2021-10-27
EP3508213A1 (en) 2019-07-10
US20190160158A1 (en) 2019-05-30
EP3290046B1 (en) 2019-01-02
HUE041837T2 (hu) 2019-05-28
EP3290046A1 (en) 2018-03-07
IL276153B (en) 2022-06-01
ZA201706929B (en) 2019-05-29
GB201519921D0 (en) 2015-12-23
RS58351B1 (sr) 2019-03-29
US20170224788A1 (en) 2017-08-10
PL2968434T3 (pl) 2018-01-31
JP2018119002A (ja) 2018-08-02
US11364288B2 (en) 2022-06-21
EP2968434A2 (en) 2016-01-20
CA2904543A1 (en) 2014-09-18
MX2020004724A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
CY1119419T1 (el) C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε)
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
MX379270B (es) Composiciones que comprenden cepas bacterianas.
MX378686B (es) Composiciones que comprenden cepas bacterianas.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MD3240554T2 (ro) Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112015011830A2 (pt) compostos e seus métodos de utilização
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX379126B (es) Formulación de factor viii.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PL3280966T3 (pl) Palnik i układ rozprowadzający do palnika